| 1 |
35563817 | Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients. | 2022 Apr 30 |
1 |
| 2 |
33783077 | The impact of micronutrient deficiency on pregnancy complications and development origin of health and disease. | 2021 Jun |
1 |
| 3 |
32238065 | Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease. | 2020 May |
1 |
| 4 |
28968204 | Prevalence of COMT Val158Met polymorphism in Eastern UP population. | 2017 Jul 31 |
1 |
| 5 |
26450530 | Fetal Val108/158Met catechol-O-methyltransferase (COMT) polymorphism and placental COMT activity are associated with the development of preeclampsia. | 2016 Jan |
3 |
| 6 |
27493964 | Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective? | 2016 |
4 |
| 7 |
25154960 | Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study. | 2014 Oct |
1 |
| 8 |
23432663 | Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis. | 2013 Aug |
1 |
| 9 |
22483294 | Catechol-o-methyltransferase and Alzheimer's disease: a review of biological and genetic findings. | 2012 May |
1 |
| 10 |
21533995 | Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease. | 2011 Jun |
1 |
| 11 |
21738693 | Comparison of endothelial progenitor cells in Parkinson's disease patients treated with levodopa and levodopa/COMT inhibitor. | 2011 |
1 |
| 12 |
20464572 | Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients. | 2010 Oct |
4 |
| 13 |
20856911 | Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). | 2010 Sep 7 |
1 |
| 14 |
21095459 | Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms. | 2010 |
2 |
| 15 |
19618311 | Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson's disease. | 2009 May-Jun |
1 |
| 16 |
19657587 | Peripheral COMT inhibition prevents levodopa associated homocysteine increase. | 2009 Oct |
3 |
| 17 |
19936145 | Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference. | 2009 Nov 3 |
1 |
| 18 |
20029636 | Possible treatment concepts for the levodopa-related hyperhomocysteinemia. | 2009 |
1 |
| 19 |
18189241 | Polymorphisms in the catechol-O-methyltransferase (COMT) gene influence plasma total homocysteine levels. | 2008 Sep 5 |
3 |
| 20 |
18505360 | Role of homocysteine in the treatment of Parkinson's disease. | 2008 Jun |
2 |
| 21 |
17264883 | Functional COMT Val158Met polymorphism, risk of acute coronary events and serum homocysteine: the Kuopio ischaemic heart disease risk factor study. | 2007 Jan 31 |
2 |
| 22 |
18064318 | Catechol-O-methyltransferase genotype is associated with plasma total homocysteine levels and may increase venous thrombosis risk. | 2007 Dec |
2 |
| 23 |
16081510 | Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. | 2006 Feb |
2 |
| 24 |
15390046 | Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. | 2005 Jan |
3 |
| 25 |
15614425 | The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. | 2005 Sep |
2 |
| 26 |
15779086 | Activation of catechol-O-methyltransferase in astrocytes stimulates homocysteine synthesis and export to neurons. | 2005 Jul |
2 |
| 27 |
15878587 | Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. | 2005 Jun |
2 |
| 28 |
15148140 | Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. | 2004 May |
1 |
| 29 |
15354384 | Dopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic cultures. | 2004 |
2 |
| 30 |
15365141 | Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? | 2004 Sep 14 |
1 |
| 31 |
12533089 | Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. | 2003 Jan |
1 |
| 32 |
12579301 | Medical hypothesis: hyperhomocysteinemia is a risk factor for estrogen-induced hormonal cancer. | 2003 Mar |
1 |
| 33 |
12075857 | 3-OMD and homocysteine plasma levels in parkinsonian patients. | 2002 Feb |
2 |
| 34 |
12371153 | On the mechanism of homocysteine pathophysiology and pathogenesis: a unifying hypothesis. | 2002 Oct |
2 |
| 35 |
11577006 | COMT genotype, micronutrients in the folate metabolic pathway and breast cancer risk. | 2001 Oct |
7 |
| 36 |
6491941 | Synthesis of bridged catechol-homocysteine derivatives as potential inhibitors of catechol O-methyltransferase. | 1984 Sep |
2 |